A Double-blind, Placebo-controlled, Dose-escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of Recombinant Human Plasma Gelsolin Added to Standard of Care in Subjects Hospitalized for Acute Community-acquired Pneumonia
Not yet recruiting
Phase of Trial: Phase I/II
Latest Information Update: 20 Mar 2018
At a glance
- Drugs Gelsolin (Primary)
- Indications Community-acquired pneumonia
- Focus Adverse reactions; Biomarker
- Sponsors BioAegis Therapeutics
- 08 Mar 2018 Status changed from planning to not yet recruiting.
- 17 Apr 2015 New trial record
- 15 Apr 2015 BioAegis Therapeutics has received regulatory advice from European authorities which support plans to initiate this trial, according to a media release.